Rowan Walrath

Lundbeck agrees to buy neuroscience firm

When Schrödinger launched more than 30 years ago, computational biology was a nascent technology. Schrödinger, a pioneer in the field, relied heavily on the Protein Data Bank (PDB), a collection of solved protein structures that got its start in the 1970s. “Getting a structure in the lab used to be—and still is—difficult,” says Karen Akinsanya, Schrödinger's president of therapeutics R&D. Back then, a single protein structure would potentially comprise a person's entire PhD or postdoctoral research, taking “years of work,” she says. The entire field of structure-based drug design took a giant leap forward with the advent of AlphaFold, the protein prediction software that launched in 2020 and this month became a Nobel Prize–winning technology . AlphaFold, which is owned by Google's DeepMind and was built on the PDB and other protein sequence databases, has used a neural network to predict the structures of now millions of proteins. Schrödinger and

Start-up emerges from stealth with $20 million to develop the new approach

Sanofi and the nuclear corporation Orano have agreed to coinvest in a new Orano subsidiary that will develop radioligands based on lead-212 α-emitting isotopes.

Merck & Co. has bought a Yale University spinout called Modifi Biosciences for $30 million up front and the potential for more than $1.3 billion in milestone payments.

Analyzing the metagenomes of microbes inside humans reveals new small molecules

With the dust settling after the US elections, chemists are trying to work out how a second Donald J. Trump presidency will affect their work and lives.

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite

President-elect Trump nominates Robert F. Kennedy Jr. to lead the Health and Human Services department

Roche is partnering with 3-year-old start-up Flare Therapeutics to discover small molecules for cancer treatment.